Kirchgesner J - Search Results

1

A methodological review of the high-dimensional propensity score in comparative-effectiveness and safety-of-interventions research finds incomplete reporting relative to algorithm development and robustness.

Martin GL, Petri C, Rozenberg J, Simon N, Hajage D, Kirchgesner J, Tubach F, Létinier L, Dechartres A. Martin GL, et al. Among authors: kirchgesner j. J Clin Epidemiol. 2024 May;169:111305. doi: 10.1016/j.jclinepi.2024.111305. Epub 2024 Feb 28. J Clin Epidemiol. 2024. PMID: 38417583 Free article. Review.

2

Focal loss of mural stratification as a radiological predictor for small bowel adenocarcinoma in Crohn's disease.

Uzzan M, Assouline V, Chambenois E, Djabbari M, Arrive L, Charpy C, Luciani A, Sobhani I, Becq A, Beaugerie L, Svrcek M, Kirchgesner J. Uzzan M, et al. Among authors: kirchgesner j. Clin Res Hepatol Gastroenterol. 2023 Dec;47(10):102246. doi: 10.1016/j.clinre.2023.102246. Epub 2023 Nov 13. Clin Res Hepatol Gastroenterol. 2023. PMID: 37967612

3

Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.

Kirchgesner J, Lemaitre M, Rudnichi A, Racine A, Zureik M, Carbonnel F, Dray-Spira R. Kirchgesner J, et al. Aliment Pharmacol Ther. 2017 Jan;45(1):37-49. doi: 10.1111/apt.13835. Epub 2016 Oct 26. Aliment Pharmacol Ther. 2017. PMID: 27781286 Free article.

4

Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study.

Martineau C, Flourié B, Wils P, Vaysse T, Altwegg R, Buisson A, Amiot A, Pineton de Chambrun G, Abitbol V, Fumery M, Hébuterne X, Viennot S, Laharie D, Beaugerie L, Nancey S, Sokol H; Goli-Crohn Study Group. Martineau C, et al. Aliment Pharmacol Ther. 2017 Dec;46(11-12):1077-1084. doi: 10.1111/apt.14371. Epub 2017 Oct 13. Aliment Pharmacol Ther. 2017. PMID: 29027693

5

Impact of Anti-tumour Necrosis Factor Agents on the Risk of Colorectal Cancer in Patients with Ulcerative Colitis: Nationwide French Cohort Study.

Charkaoui M, Hajage D, Tubach F, Beaugerie L, Kirchgesner J. Charkaoui M, et al. Among authors: kirchgesner j. J Crohns Colitis. 2022 Jul 14;16(6):893-899. doi: 10.1093/ecco-jcc/jjab184. J Crohns Colitis. 2022. PMID: 34657962

6

Calibrating Real-World Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Crohn's Disease.

Kirchgesner J, Desai RJ, Beaugerie L, Kim SC, Schneeweiss S. Kirchgesner J, et al. Clin Pharmacol Ther. 2022 Jan;111(1):179-186. doi: 10.1002/cpt.2304. Epub 2021 Jun 14. Clin Pharmacol Ther. 2022. PMID: 34027993 Free article.

7

Use of Proton Pump Inhibitors and Risk of Pancreatic Cancer: A Nationwide Case-Control Study Based on the French National Health Data System (SNDS).

Lassalle M, Le Tri T, Afchain P, Camus M, Kirchgesner J, Zureik M, Dray-Spira R. Lassalle M, et al. Among authors: kirchgesner j. Cancer Epidemiol Biomarkers Prev. 2022 Mar 1;31(3):662-669. doi: 10.1158/1055-9965.EPI-21-0786. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 34937794 Free PMC article.

8

Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease.

Kirchgesner J, Desai RJ, Schneeweiss MC, Beaugerie L, Schneeweiss S, Kim SC. Kirchgesner J, et al. Gut. 2022 Sep;71(9):1781-1789. doi: 10.1136/gutjnl-2022-327002. Epub 2022 Apr 6. Gut. 2022. PMID: 35387877 Free article.

9

Emulation of a randomized controlled trial in ulcerative colitis with US and French claims data: Infliximab with thiopurines compared to infliximab monotherapy.

Kirchgesner J, Desai RJ, Schneeweiss MC, Beaugerie L, Kim SC, Schneeweiss S. Kirchgesner J, et al. Pharmacoepidemiol Drug Saf. 2022 Feb;31(2):167-175. doi: 10.1002/pds.5356. Epub 2021 Sep 26. Pharmacoepidemiol Drug Saf. 2022. PMID: 34498314 Free article. Clinical Trial.

10

Risk of first ischaemic stroke and use of antidopaminergic antiemetics: nationwide case-time-control study.

Bénard-Laribière A, Hucteau E, Debette S, Kirchgesner J, Bezin J, Pariente A. Bénard-Laribière A, et al. Among authors: kirchgesner j. BMJ. 2022 Mar 23;376:e066192. doi: 10.1136/bmj-2021-066192. BMJ. 2022. PMID: 35321876 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

95 results

Search Page